Association of Angiotensin Receptor Blockers with Incident Parkinson Disease in Patients with Hypertension: A Retrospective Cohort Study - 29/07/22

Doi : 10.1016/j.amjmed.2022.04.029

Hsiu-Chen Lin, MD, PhD ^a,^b, Yuan-Fu Tseng, MD ^c, Ai-Ling Shen, MD ^c, Jane Chen-Jui Chao, PhD ^d,^e, Chien-Yeh Hsu, PhD ^f, Hsiu-Li Lin, MD, MSc ^c,^g,^⁎
^a Department of Clinical Pathology, Taipei Medical University Hospital, Taipei, Taiwan
^b Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
^c Department of Neurology, Sijhih Cathay General Hospital, New Taipei City, Taiwan
^d School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan
^e Nutrition Research Center, Taipei Medical University Hospital, Taipei, Taiwan
^f Department of Information Management, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan
^g College of Medicine, National Tsing Hua University, Hsinju City, Taiwan

^⁎Requests for reprints should be addressed to Hsiu-Li Lin, No.2, Ln. 59, Jiancheng Rd., Sijhih Dist, New Taipei City 221, Taiwan.No.2, Ln. 59, Jiancheng Rd., Sijhih DistNew Taipei City221Taiwan

Abstract

Background

Angiotensin receptor blockers (ARBs), which are commonly used antihypertensives, have been proposed to lower the risk of Parkinson disease by reducing oxidative stress based on animal and in vitro studies. Thus, this study aimed to test this association in patients with newly diagnosed hypertension.

Methods

This retrospective cohort study enrolled 107,207 patients with newly diagnosed hypertension between 2001 and 2013. The hazard ratios for Parkinson disease were calculated for ARB treatment compared with those who never used ARBs and among the 5 subgroups receiving different cumulative ARB dosages.

Results

We identified 527 (1.1%) Parkinson disease cases among patients with ARB treatment in a median observation period of 8.4 years compared to the 1,255 (2.2%) Parkinson disease cases among those without ARB treatment in a median observation period of 6.8 years. Overall, risk for developing Parkinson disease was statistically lower in the ARB-treated group with a hazard ratio of 0.56 (95% confidence interval: 0.51-0.63) than those without ARB.

Conclusions

ARB treatment was associated with a statistically important reduction of Parkinson disease risk in patients with newly diagnosed hypertension. Therefore, ARB may constitute an effective neuroprotective strategy to lower Parkinson disease risk in such patients.

Le texte complet de cet article est disponible en PDF.

Keywords : Angiotensin receptor blocker, Hypertension, National Health Insurance Research Dataset, Parkinson disease, Renin-angiotensin system

Plan

Study Population Characteristics

Association of ARBs and Parkinson Disease

Association of ARB Dose and Parkinson Disease

Discussion

Limitations

Conclusion

	Funding: None.
	Conflicts of Interest: None.
	Authorship: All authors had access to the data and a role in writing this manuscript.

Export

Vol 135 - N° 8

P. 1001-1007 - août 2022 Retour au numéro

Article précédent

Cocaine and the Long-Term Risk of Cardiovascular Disease in Women
U. Vivian Ukah, Brian J. Potter, Gilles Paradis, Nancy Low, Aimina Ayoub, Nathalie Auger

| Article suivant

Transfusion in Older Anemic Patients: Should the Troponin Value Be Taken into Account?
Manon Thevenin, Sophie Putot, Patrick Manckoundia, Alain Putot

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Association of Angiotensin Receptor Blockers with Incident Parkinson Disease in Patients with Hypertension: A Retrospective Cohort Study - 29/07/22

Abstract

Background

Methods

Results

Conclusions

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL